Louisiana State Employees Retirement System lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,400 shares of the pharmaceutical company’s stock after selling 1,600 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Vertex Pharmaceuticals were worth $2,221,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in VRTX. BlackRock Inc. lifted its position in shares of Vertex Pharmaceuticals by 3.2% in the third quarter. BlackRock Inc. now owns 19,935,843 shares of the pharmaceutical company’s stock worth $3,842,436,000 after purchasing an additional 625,328 shares in the last quarter. Vanguard Group Inc lifted its position in shares of Vertex Pharmaceuticals by 1.2% in the third quarter. Vanguard Group Inc now owns 18,775,252 shares of the pharmaceutical company’s stock worth $3,618,743,000 after purchasing an additional 213,550 shares in the last quarter. FMR LLC lifted its position in shares of Vertex Pharmaceuticals by 10.5% in the third quarter. FMR LLC now owns 18,071,478 shares of the pharmaceutical company’s stock worth $3,483,097,000 after purchasing an additional 1,714,071 shares in the last quarter. Jennison Associates LLC lifted its position in shares of Vertex Pharmaceuticals by 22.5% in the third quarter. Jennison Associates LLC now owns 6,202,493 shares of the pharmaceutical company’s stock worth $1,195,468,000 after purchasing an additional 1,139,486 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Vertex Pharmaceuticals by 1.0% in the third quarter. Renaissance Technologies LLC now owns 4,089,117 shares of the pharmaceutical company’s stock worth $788,136,000 after purchasing an additional 38,500 shares in the last quarter. Institutional investors own 93.57% of the company’s stock.

In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 2,155 shares of the company’s stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $175.36, for a total value of $377,900.80. Following the transaction, the executive vice president now directly owns 48,907 shares in the company, valued at $8,576,331.52. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Paul M. Silva sold 809 shares of the company’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $186.52, for a total transaction of $150,894.68. Following the completion of the transaction, the senior vice president now owns 16,896 shares in the company, valued at $3,151,441.92. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,702 shares of company stock worth $2,751,388. Corporate insiders own 0.75% of the company’s stock.

A number of analysts have recently commented on the stock. BidaskClub raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, January 10th. Citigroup cut their price objective on shares of Vertex Pharmaceuticals from $206.00 to $205.00 and set a “buy” rating on the stock in a research report on Friday, January 4th. Raymond James lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $165.71 price objective on the stock. in a research report on Wednesday, January 2nd. Zacks Investment Research lowered shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, December 31st. Finally, Morgan Stanley cut their price objective on shares of Vertex Pharmaceuticals from $211.00 to $210.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 19th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $200.61.

NASDAQ VRTX opened at $186.68 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.59 and a current ratio of 3.71. Vertex Pharmaceuticals Incorporated has a 1 year low of $144.07 and a 1 year high of $194.92. The firm has a market cap of $48.09 billion, a price-to-earnings ratio of 233.35, a PEG ratio of 1.43 and a beta of 1.54.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 24th. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.02 by $0.07. Vertex Pharmaceuticals had a net margin of 22.87% and a return on equity of 22.92%. The firm had revenue of $784.54 million for the quarter, compared to analyst estimates of $782.95 million. During the same period in the prior year, the firm posted $0.53 earnings per share. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 2.55 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.watchlistnews.com/vertex-pharmaceuticals-incorporated-vrtx-shares-sold-by-louisiana-state-employees-retirement-system/2749461.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

Featured Article: What is the Dividend Aristocrat Index?

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.